文献速递神经肿瘤

MicroRNA作为胶质母细胞瘤潜在生物标志物的诊断准确性:系统综述与Meta分析

Exploring the Diagnostic Test Accuracy of MicroRNAs as Potential Biomarkers for Glioblastoma: Systematic Review and Meta-Analysis.
PubMed 文献 · Neurosurgery · 2025-10-23

该系统综述与Meta分析评估了基于miRNA的液体活检对胶质母细胞瘤(GBM)的诊断准确性。纳入15篇文章、28项miRNA评估,汇总敏感度和特异度分别为0.84和0.89,阴性似然比较低,支持miRNA(尤其miR-21)用于GBM诊断与排除。

要点

  • miRNA液体活检对GBM诊断的汇总敏感度为0.84,特异度为0.89。
  • 非癌症和非GBM脑肿瘤对照的阴性似然比均较低,有助于排除诊断。
  • miR-21显示出显著的GBM诊断效用,但需临床验证与技术标准化。

核心结论

  • miRNA(尤其miR-21)对GBM诊断具有显著效用,并可帮助排除非GBM患者。
  • 结果支持进一步开发基于miRNA的液体活检用于GBM诊断,但需强调临床验证与技术标准化。

研究设计与样本

  • 从1829项研究中纳入15篇文章,包含28项miRNA评估,涉及551例GBM患者的868份样本和578例对照的811份样本。
  • 通过构建2×2列联表评估诊断性能,采用汇总和个体敏感度、特异度、阳性似然比、阴性似然比及诊断比值比指标。

主要发现

  • miRNA诊断GBM的汇总敏感度为0.84(95%可信区间:0.78-0.89),汇总特异度为0.89(95%可信区间:0.84-0.92)。
  • 敏感度异质性为66%,特异度异质性为39%。
  • 非癌症对照的阴性似然比为0.20(95%可信区间:0.15-0.27),非GBM脑肿瘤对照的阴性似然比为0.24(95%可信区间:0.14-0.35)。

临床怎么用

  • miRNA液体活检可作为GBM微创诊断的潜在工具,尤其miR-21值得关注。
  • 低阴性似然比提示该检测有助于在非GBM患者中排除诊断。

局限性

  • 数据集存在异质性,敏感度异质性为66%,特异度异质性为39%。
  • 需进一步临床验证和技术标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Glioblastoma (GBM) is the most common and devastating primary malignant brain tumor. Early diagnosis and treatment are essential for improving patient outcomes, and microRNA (miRNA)-based liquid biopsies offer a promising, minimally invasive diagnostic approach. The aim of this systematic review was to evaluate the diagnostic accuracy of miRNA-based liquid biopsies for GBM. METHODS: A comprehensive systematic review was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using Ovid Medline and Embase. Studies were selected up to October 16, 2024, based on predefined inclusion criteria. Data were extracted to construct 2 × 2 contingency tables, and diagnostic performance was evaluated using pooled and individual sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio metrics. RESULTS: From 1829 identified studies, 15 articles met inclusion criteria, comprising 28 miRNA evaluations with 868 samples from 551 GBM patients and 811 samples from 578 controls. The pooled sensitivity and specificity for miRNA-based diagnostic biomarkers for GBM were 0.84 (95% credible interval [CI]: 0.78-0.89) and 0.89 (95% CI: 0.84-0.92), respectively. Heterogeneity across the data set was 66% for sensitivity and 39% for specificity. Negative likelihood ratios for both noncancer (0.20, 95% CI: 0.15-0.27) and non-GBM brain tumor (0.24, 95% CI: 0.14-0.35) controls were low. CONCLUSION: miRNAs, especially miR-21, demonstrate significant utility for diagnosis of GBM and for ruling out diagnosis in patients who do not have GBM. These findings support the further development of miRNA-based liquid biopsies for GBM diagnosis with emphasis on clinical validation and standardization of technique.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Niznik T, York A, Bialek S, et al. Exploring the Diagnostic Test Accuracy of MicroRNAs as Potential Biomarkers for Glioblastoma: Systematic Review and Meta-Analysis. Neurosurgery. 2025. PMID: 41128517. doi:10.1227/neu.0000000000003813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。